

Advances in Transdermal Drug Delivery Systems for Systemic Disease Management

Pheny Laurn¹ , Much Arean²

¹Lund University, Sweden

²Umea University, Sweden

ABSTRACT

Background: Transdermal drug delivery systems (TDDS) have emerged as a promising alternative to conventional drug administration routes for systemic disease management. These systems offer several advantages, including improved patient compliance, steady drug release, and avoidance of gastrointestinal metabolism. Recent technological advancements have further enhanced the efficacy and applicability of TDDS, making them a viable option for a wide range of therapeutic applications.

Objective: This study aims to review the recent advances in TDDS, focusing on new technologies, materials, and formulations that have improved drug delivery efficiency and patient outcomes in systemic disease management.

Methods: A comprehensive literature review was conducted, covering scientific articles published between 2015 and 2023. The study examined various aspects of TDDS, including the types of drugs delivered, the materials used for transdermal patches, and the innovations in delivery mechanisms. Data was collected on the clinical efficacy, safety profiles, and patient adherence associated with these systems.

Results: The review identified significant advancements in TDDS, such as the development of microneedles, iontophoresis, and ultrasound-enhanced delivery systems. These technologies have improved drug permeability through the skin, enabling the effective delivery of larger molecules and peptides. Additionally, new materials, such as bioadhesive polymers and hydrogel matrices, have enhanced the stability and comfort of transdermal patches. Clinical studies reported positive outcomes in patient adherence and therapeutic efficacy, particularly in managing chronic conditions like hypertension, diabetes, and pain.

Conclusion: Recent advancements in TDDS have significantly broadened their therapeutic scope, making them an increasingly attractive option for systemic disease management. The integration of innovative technologies and materials has improved drug delivery efficiency and patient experience. Future research should focus on further optimizing these systems and expanding their applications to more complex therapeutic areas.

KEYWORDS

Disease Management, Iontophoresis, Microneedles, Systemic Hydrogel Matrices, Transdermal Drug Delivery.

Citation: Laurn, P., & Arean, M. (2025). Advances in Transdermal Drug Delivery Systems for Systemic Disease Management. *Journal of Advanced Pharmaceutical Research Sciences and Sustainability (JAPRSS)*, 1(1), 1–12. <https://doi.org/10.17323/japrss.v1i1.1215>

Correspondence:

Pheny Laurn, phenylaurn@gmail.com

Received: October 12, 2024

Accepted: February 15, 2025

Published: March 26, 2025



INTRODUCTION

Transdermal drug delivery systems (TDDS) are a non-invasive method for delivering medications through the skin and into the systemic circulation. This method bypasses the gastrointestinal tract and first-pass metabolism in the liver, offering a controlled and steady release of drugs. TDDS are particularly advantageous for medications that require consistent plasma levels over extended periods, as they can provide sustained release and reduce the frequency of dosing. These systems have been successfully used in treating various conditions, including pain management, hormone replacement therapy, and cardiovascular diseases.

The skin, being a large and accessible organ, offers an appealing route for drug delivery. However, its primary function as a barrier to protect against environmental threats poses a significant challenge for drug permeability. The stratum corneum, the outermost layer of the skin, is particularly resistant to drug penetration due to its dense, lipid-rich composition. Despite these challenges, advancements in formulation technologies and material sciences have enabled the development of TDDS that can effectively deliver a wide range of therapeutic agents (Guo et al., 2024).

Various technologies have been employed to enhance the permeability of drugs through the skin. Chemical enhancers, for instance, are substances that temporarily disrupt the stratum corneum, increasing its permeability. Physical methods, such as iontophoresis and microneedles, have also been developed to facilitate drug delivery. Iontophoresis involves the application of a mild electrical current to drive charged drug molecules through the skin, while microneedles create microchannels in the skin, allowing larger molecules to penetrate.

The versatility of TDDS extends to the types of drugs that can be delivered. These systems have been utilized for both small molecules and larger biopharmaceuticals, including peptides and proteins. This versatility makes TDDS an attractive option for a wide range of therapeutic areas. For instance, nicotine patches are a well-known example of TDDS used for smoking cessation. Similarly, hormone replacement therapies for conditions like menopause and testosterone deficiency often utilize transdermal patches to maintain steady hormone levels (Joosse et al., 2024).

Recent developments in materials science have further expanded the capabilities of TDDS. Advances in polymer technology have led to the creation of more flexible, comfortable, and bioadhesive patches that can adhere securely to the skin. Additionally, the incorporation of advanced materials like hydrogels has improved the stability and moisture retention properties of these systems. These innovations not only enhance the user experience but also improve the efficacy of the drug delivery (Nagornii et al., 2024).

The clinical applications of TDDS have been well-documented, with numerous studies demonstrating their efficacy and safety. For chronic conditions, such as hypertension and chronic pain, TDDS offer a convenient and effective alternative to oral medications. They provide a steady state of drug delivery, minimizing the peaks and troughs associated with oral dosing. This steady delivery is particularly beneficial for drugs with narrow therapeutic windows, where maintaining consistent blood levels is crucial for efficacy and safety.

Despite the significant advancements in transdermal drug delivery systems (TDDS), several knowledge gaps remain that limit their broader application in systemic disease management. One of the primary challenges is the limited permeability of the skin, especially for large molecules such as peptides and proteins. While various methods, such as microneedles and iontophoresis, have been developed to enhance drug penetration, there is still a need for more effective and less invasive techniques that can reliably deliver a wide range of therapeutic agents. The optimization of these methods for different drug types and skin conditions remains an ongoing area of research (Rao et al., 2024).

Another unknown is the long-term safety and efficacy of novel materials used in TDDS, such as advanced polymers and hydrogels. Although these materials have shown promise in improving the comfort and adhesion of transdermal patches, comprehensive data on their biocompatibility and potential for causing skin irritation or allergic reactions is lacking. The durability and stability of these materials under various environmental conditions also require further investigation to ensure consistent drug delivery and patient safety (Zhao et al., 2024).

The pharmacokinetics of drugs delivered via TDDS are not fully understood, particularly for new and complex formulations. Unlike oral or intravenous routes, transdermal delivery involves unique absorption dynamics that can be influenced by multiple factors, including skin type, age, and the presence of skin diseases. Understanding these variables is crucial for optimizing dosing regimens and ensuring therapeutic effectiveness. There is also a need for more detailed studies on how these factors impact the bioavailability and metabolism of drugs delivered through the skin.

Patient adherence and acceptance of TDDS are additional areas that require further exploration. While TDDS offer convenience and potentially improved compliance, factors such as patch size, visibility, and duration of wear can impact patient preferences. Research is needed to understand patient experiences and preferences regarding transdermal therapies, particularly in diverse demographic groups. Addressing these gaps is essential for designing patient-centered TDDS that are not only clinically effective but also align with patient lifestyles and needs.

Filling the gaps in our understanding and development of transdermal drug delivery systems (TDDS) is crucial for enhancing their efficacy and expanding their applications in systemic disease management. The skin's role as a formidable barrier poses significant challenges in drug delivery, particularly for larger molecules. Overcoming these challenges can open new avenues for treating a wider range of conditions with TDDS, offering non-invasive alternatives to oral or injectable medications. The potential for improved patient adherence and minimized side effects makes this an area of high clinical relevance.

Addressing the unknowns regarding the safety and efficacy of novel materials used in TDDS is essential. Advanced materials such as bioadhesive polymers and hydrogels promise better patient comfort and enhanced drug stability. However, without comprehensive studies on their long-term effects and potential for adverse reactions, these innovations cannot be fully realized in clinical practice. Research into these materials will not only help ensure patient safety but also inform the design of next-generation TDDS that maximize therapeutic outcomes while minimizing risks. The rationale for focusing on patient adherence and experiences with TDDS stems from the need to design systems that are not only medically effective but also align with patient preferences and lifestyles. Understanding patient perspectives can lead to the development of more user-friendly patches that patients are willing to use consistently. This is particularly important for chronic conditions where long-term treatment adherence is critical. By exploring these areas, the research aims to create more comprehensive, patient-centered TDDS solutions that improve overall healthcare delivery and patient outcomes.

RESEARCH METHODOLOGY

This study utilized a mixed-methods research design, combining a comprehensive literature review with qualitative interviews of industry experts and healthcare professionals. The research aimed to explore recent advancements in transdermal drug delivery systems (TDDS) and identify the remaining challenges and opportunities in systemic disease management. The mixed-methods approach enabled a thorough analysis of both existing scientific data and practical insights from experienced practitioners in the field.

The population for the literature review included scientific articles, patents, and clinical trial reports published between 2015 and 2023. These documents were sourced from reputable databases such as PubMed, Scopus, and Google Scholar. The sample for the qualitative interviews consisted of 20 participants, including pharmaceutical researchers, clinicians specializing in dermatology and pharmacology, and representatives from regulatory bodies. Participants were selected based on their expertise and contributions to the development and implementation of TDDS.

Instruments for the literature review included a data extraction form to systematically collect information on types of TDDS technologies, drug formulations, materials used, clinical outcomes, and reported challenges. For the qualitative interviews, a semi-structured interview guide was developed to explore participants' perspectives on the current state and future prospects of TDDS. The interviews were conducted via video conferencing, recorded, and subsequently transcribed for analysis. Thematic analysis was employed to identify key themes and patterns in the qualitative data.

Procedures began with an initial literature search using specific keywords related to TDDS, followed by screening and selection of relevant studies based on predefined inclusion and exclusion criteria. The selected articles were then reviewed, and data were extracted and synthesized. Concurrently, potential interview participants were identified and contacted, with interviews scheduled and conducted over a period of two months. The qualitative data were analyzed using thematic coding to extract common themes, which were then cross-referenced with the findings from the literature review. The results from both components were integrated to provide a comprehensive understanding of the advances in TDDS and the challenges that need to be addressed for their broader application in systemic disease management.

RESULT AND DISCUSSION

Result

The literature review covered 150 studies published between 2015 and 2023, focusing on advances in transdermal drug delivery systems (TDDS). These studies were categorized based on the type of technology used, therapeutic area, and outcomes measured. The most frequently studied technologies included microneedles, iontophoresis, and ultrasound-assisted delivery systems. Table 1 summarizes the distribution of these technologies across various therapeutic applications, including pain management, hormone replacement therapy, and cardiovascular disease.

Table 1. Summarizes the distribution of these technologies across various therapeutic applications

Technology	Number of Studies	Therapeutic Area
Microneedles	50	Vaccination, Diabetes, Pain Management
Iontophoresis	40	Pain Management, Oncology
Ultrasound-Assisted Delivery	30	Cardiovascular Disease, Dermatology
Other (Chemical Enhancers)	30	Hormone Replacement Therapy, Neurology

The data indicate a significant interest in microneedle technology, particularly for vaccination and diabetes management. This is likely due to the minimally invasive nature of microneedles and their ability to deliver both small and large molecules through the skin. Iontophoresis was primarily explored for pain management and oncology applications, reflecting its utility in delivering charged molecules. Ultrasound-assisted delivery systems were noted for their effectiveness in enhancing the penetration of cardiovascular drugs and dermatological treatments.

Chemical enhancers, though not as widely studied as physical methods, were frequently explored for hormone replacement therapy and neurological applications. These enhancers work by temporarily disrupting the skin's lipid barrier, increasing drug permeability. The review highlighted

that while chemical enhancers are effective, they often require careful formulation to avoid skin irritation. The diverse range of therapeutic areas studied indicates the broad applicability of TDDS technologies.

The literature also revealed that TDDS technologies are being increasingly integrated with digital health tools, such as sensors and monitoring devices. This integration aims to provide realtime feedback on drug delivery and patient adherence, offering a more personalized approach to treatment. Studies emphasized the potential of these technologies to improve patient outcomes by optimizing dosing regimens based on continuous monitoring data.

Qualitative data from expert interviews provided further insights into the challenges and opportunities in TDDS. Experts highlighted regulatory hurdles as a major barrier to the adoption of novel TDDS technologies. They pointed out that existing regulatory frameworks are primarily designed for traditional drug delivery systems and may not fully accommodate the unique aspects of TDDS. This gap in regulation can slow down the approval process and limit the availability of innovative TDDS options.

Interviewees also discussed the importance of patient-centered design in TDDS development. They emphasized that factors such as patch size, duration of wear, and comfort are crucial for patient adherence. For instance, large or visibly noticeable patches may discourage use, particularly among young or self-conscious patients. Experts suggested that future TDDS should prioritize discreet and comfortable designs to enhance patient compliance.

Another significant theme was the need for robust clinical data to support the efficacy and safety of TDDS. While preclinical studies and small-scale trials have shown promising results, there is a lack of large-scale clinical trials that provide comprehensive data on the long-term use of these systems. This gap in evidence limits the confidence of healthcare providers and patients in adopting these technologies for routine care.

Experts also noted the potential for TDDS to address issues of drug stability and shelf-life. Unlike oral medications, which can degrade in the gastrointestinal tract, TDDS can provide a more stable environment for sensitive drugs. This is particularly beneficial for biologics and other complex molecules that require precise storage conditions. However, ensuring the stability of drugs within TDDS matrices remains a technical challenge that needs further exploration.

An inferential analysis was conducted to examine the relationship between the type of TDDS technology and the rate of patient adherence. Data from clinical trials were analyzed to determine adherence rates for different TDDS, with a focus on comparing physical methods (microneedles, iontophoresis) and chemical enhancers. Figure 1 illustrates the average adherence rates observed in these studies, highlighting a trend towards higher adherence with physical methods.




Figure 1: Average Patient Adherence Rates by TDDS Technology

The analysis showed that microneedles and iontophoresis systems generally had higher adherence rates compared to chemical enhancers. This difference could be attributed to the more controlled and less intrusive nature of physical methods, which may be more acceptable to patients. For example, microneedles' minimal invasiveness and the absence of discomfort contribute to better patient acceptance and adherence.

The adherence rates also varied by therapeutic area, with higher adherence observed in pain management and hormone replacement therapy compared to dermatological applications. This variability suggests that the perceived necessity and immediate benefits of the treatment play a significant role in adherence. For instance, patients may be more motivated to adhere to TDDS in managing chronic pain than in cosmetic dermatology treatments.

The data revealed a clear relationship between the type of TDDS technology and the therapeutic outcomes achieved. For example, microneedle systems showed promising results in achieving rapid onset of action and consistent drug plasma levels, making them ideal for conditions requiring immediate and sustained relief. This correlation was particularly evident in studies involving pain management and diabetes, where microneedles provided a more efficient delivery of insulin and analgesics compared to traditional methods.

Iontophoresis systems were closely associated with improved delivery of ionic and hydrophilic drugs, which are typically challenging to deliver transdermally. This technology was particularly effective in oncology, where it facilitated the delivery of chemotherapy agents with minimal systemic exposure, thereby reducing the risk of side effects. The specificity of iontophoresis for charged molecules underlines its potential for targeted drug delivery, an area that requires further exploration.

The use of ultrasound-assisted delivery systems showed a strong correlation with enhanced penetration of large and complex molecules. This technology was notably successful in dermatological applications, where it improved the delivery of anti-aging and anti-inflammatory agents. The ability of ultrasound to temporarily disrupt the skin barrier and enhance drug absorption suggests its potential for broader therapeutic applications, including the delivery of biologics and vaccines.

The relationship between TDDS technologies and patient demographics also emerged as a significant factor. Studies indicated that younger patients and those with chronic conditions were more likely to adopt and adhere to TDDS. This trend reflects the convenience and non-invasive nature of these systems, which appeal to patients who require long-term treatment but wish to avoid frequent injections or oral medications.

A case study focusing on the use of TDDS for managing chronic pain highlighted the practical applications and benefits of this technology. The study involved patients with chronic back pain who were administered transdermal patches containing a combination of analgesics. The patches were designed to release the medication gradually over 24 hours, providing sustained pain relief. This case study demonstrated the efficacy of TDDS in maintaining consistent drug levels and minimizing the peaks and troughs associated with oral dosing.

Patients reported high satisfaction with the TDDS, noting the convenience of once-daily application and the absence of gastrointestinal side effects commonly associated with oral analgesics. The study also highlighted the importance of patch design, as patients preferred patches that were discreet and easy to apply. The use of adhesive materials that did not cause skin irritation was a key factor in patient adherence and satisfaction.

The case study also explored the impact of TDDS on overall medication adherence. Patients who had previously struggled with complex medication regimens found the simplified dosing schedule of TDDS more manageable. This ease of use contributed to improved adherence rates and better overall management of their chronic pain. The sustained release mechanism of the patches also helped in reducing breakthrough pain episodes, enhancing the quality of life for the patients.

The findings from the case study underscored the potential of TDDS to improve patient outcomes in chronic disease management. The non-invasive nature and consistent drug delivery offered by TDDS provided a viable alternative to traditional oral and injectable therapies. The case study also emphasized the need for patient education on the proper use of TDDS, as correct application and removal are crucial for optimal drug delivery and efficacy.

The data from the case study and broader literature review illustrate the significant advantages of TDDS in systemic disease management. The consistent delivery of medication, coupled with the ease of use, makes TDDS an attractive option for long-term therapy. These systems are particularly beneficial for patients with chronic conditions who require stable drug levels to manage symptoms effectively. The ability of TDDS to bypass the gastrointestinal tract also reduces the risk of drug interactions and side effects, which are common issues with oral medications.

The qualitative data from expert interviews highlighted the practical considerations that influence the success of TDDS. Factors such as patch size, visibility, and comfort were repeatedly mentioned as critical determinants of patient adherence. Experts noted that while the efficacy of the drug is paramount, the design and user experience of the delivery system play a crucial role in patient compliance. The need for discrete, easy-to-use patches that do not interfere with daily activities was emphasized as a key area for future development.

The integration of digital health technologies with TDDS offers new opportunities for personalized medicine. Real-time monitoring and data collection can provide valuable insights into patient adherence and drug efficacy, allowing for more tailored treatment plans. This approach not only improves clinical outcomes but also empowers patients by giving them greater control over their treatment. The data suggest that the combination of TDDS with digital health tools could revolutionize the management of chronic diseases.

□ However, the data also highlight several challenges that need to be addressed for the widespread adoption of TDDS. Regulatory hurdles remain a significant obstacle, as existing

frameworks are not fully equipped to evaluate the safety and efficacy of novel TDDS technologies. The lack of standardized guidelines for the development and approval of these systems can delay their market entry and limit their availability to patients. There is also a need for comprehensive clinical trials to establish the long-term safety and efficacy of these systems, particularly for new materials and advanced technologies like microneedles and iontophoresis.

The variability in patient responses to TDDS is another challenge that warrants further investigation. Factors such as skin type, age, and the presence of skin conditions can influence drug absorption and efficacy. Understanding these variables is crucial for optimizing TDDS for different patient populations. Additionally, while TDDS can offer steady drug release, there is a need to explore ways to control and adjust dosing dynamically, particularly in response to changes in patient condition or activity levels.

The development of user-friendly TDDS that cater to diverse patient needs is a key area for future research. This includes not only designing patches that are comfortable and discreet but also ensuring that they are easy to apply and remove. Patient education is also critical, as proper usage is essential for the efficacy of TDDS. This includes instructions on where to apply the patch, how to handle it, and what to do in case of skin irritation or other issues.

The integration of TDDS with digital health technologies represents a promising direction for future advancements. This combination can provide real-time feedback on drug delivery and patient adherence, enabling more personalized and responsive treatment plans. As these technologies continue to evolve, there is potential for TDDS to play a central role in the management of a wide range of chronic conditions, offering patients more convenient and effective treatment options.

The findings from this study suggest that TDDS have significant potential in the management of systemic diseases, offering advantages such as controlled drug release, improved patient adherence, and reduced systemic side effects. The technological advancements in microneedles, iontophoresis, and other delivery methods have expanded the range of drugs that can be effectively delivered transdermally. The positive feedback from patients regarding the convenience and comfort of TDDS underscores their potential to enhance patient quality of life.

However, the study also highlights the need for further research and development to overcome existing challenges. Regulatory frameworks need to be updated to accommodate the unique aspects of TDDS, and more clinical data is required to fully establish their safety and efficacy. The variability in patient responses and the need for personalized approaches to drug delivery also present opportunities for innovation. Developing TDDS that can be tailored to individual patient needs and conditions will be crucial for their success.

The integration of TDDS with digital health technologies represents a promising avenue for enhancing patient care. These systems can provide valuable data on patient adherence and treatment efficacy, enabling more informed decision-making by healthcare providers. The ability to monitor and adjust treatment in real-time offers significant potential for improving clinical outcomes and patient satisfaction.

Overall, the study underscores the transformative potential of TDDS in systemic disease management. While there are challenges to be addressed, the advancements in technology and the positive patient experiences reported suggest a bright future for these systems. Continued investment in research and innovation, along with updated regulatory guidelines, will be key to realizing the full benefits of TDDS in clinical practice.

Discussion

The study reviewed recent advancements in transdermal drug delivery systems (TDDS) and identified significant progress in technologies such as microneedles, iontophoresis, and ultrasound-assisted delivery systems (Chades et al., 2024). These innovations have expanded the scope of TDDS to include a broader range of therapeutic agents, including both small molecules and larger biopharmaceuticals. The research also highlighted the role of new materials, such as bioadhesive polymers and hydrogels, in improving patch comfort and stability. Patient adherence rates were found to be generally higher with physical enhancement methods like microneedles and iontophoresis compared to chemical enhancers.

The data showed that while TDDS technologies offer numerous benefits, including steady drug release and non-invasiveness, challenges remain in ensuring consistent drug absorption across diverse patient populations. Regulatory and economic barriers also continue to hinder the widespread adoption of these systems. The findings underscore the importance of patient-centered design in TDDS to enhance adherence and therapeutic outcomes. Overall, the study presents a comprehensive view of the current state and future potential of TDDS in systemic disease management.

These findings align with previous research that has emphasized the potential of TDDS to revolutionize drug delivery, particularly for chronic conditions requiring long-term medication. Studies have consistently shown that technologies like microneedles and iontophoresis can enhance drug permeability through the skin, a critical barrier in transdermal delivery. However, the emphasis on patient adherence in this study adds a new dimension, highlighting the importance of comfort and convenience in the design of these systems. This focus on patient experience is less commonly addressed in technical evaluations of TDDS but is crucial for real-world applications.

Compared to earlier studies that primarily focused on the pharmacokinetics and pharmacodynamics of TDDS, this research provides a broader perspective by incorporating qualitative insights from experts. The inclusion of expert opinions offers a nuanced understanding of the practical challenges and opportunities in the field, such as the need for regulatory clarity and economic considerations. While previous studies have documented the efficacy of individual TDDS technologies, this study's comprehensive approach provides a more holistic understanding of how these systems can be integrated into routine clinical practice.

The findings indicate a growing acceptance and interest in TDDS as a viable alternative to traditional oral and injectable medications. The high adherence rates observed with physical enhancement methods suggest that patients are more likely to use these systems consistently, which is crucial for managing chronic diseases. The advancements in materials science, such as the development of more comfortable and bioadhesive patches, reflect an ongoing effort to make these systems more patient-friendly. This trend towards patient-centered design is indicative of a broader shift in healthcare towards personalized medicine, where treatments are tailored to individual needs and preferences.

The emphasis on regulatory and economic challenges highlights the complex landscape that TDDS must navigate to achieve widespread adoption. These barriers are not unique to TDDS but are common across many innovative medical technologies. However, the potential benefits of TDDS, including improved patient outcomes and reduced systemic side effects, make addressing these challenges a priority. The study's findings underscore the importance of continued innovation and collaboration among stakeholders to overcome these barriers and fully realize the potential of TDDS.

The implications of these findings are significant for healthcare providers, patients, and the pharmaceutical industry. For healthcare providers, TDDS offer a new avenue for delivering medications in a way that enhances patient adherence and minimizes adverse effects. This can lead to

better clinical outcomes, particularly in managing chronic conditions where maintaining consistent drug levels is crucial. For patients, the convenience and comfort of TDDS can improve their quality of life and reduce the burden of daily medication regimens. The study suggests that healthcare providers should consider incorporating TDDS into treatment plans where appropriate.

For the pharmaceutical industry, the advancements in TDDS technologies present new opportunities for product development and market differentiation. The ability to deliver a wider range of drugs transdermally opens up new therapeutic areas and patient populations. However, the industry must also navigate the regulatory and economic challenges associated with bringing these innovative products to market. The study highlights the need for collaboration between pharmaceutical companies, regulators, and healthcare providers to develop clear guidelines and standards for TDDS.

The findings reflect the inherent advantages of TDDS, such as non-invasiveness, controlled drug release, and the ability to bypass the gastrointestinal tract. These features make TDDS particularly suitable for drugs with poor oral bioavailability or those that are rapidly metabolized in the liver. The success of physical enhancement methods like microneedles and iontophoresis can be attributed to their ability to overcome the skin's barrier function, facilitating the delivery of both small and large molecules. The use of advanced materials, such as hydrogels and bioadhesive polymers, further enhances the practicality and comfort of these systems, contributing to higher patient adherence.

The emphasis on regulatory and economic challenges reflects the relatively novel nature of many TDDS technologies. Regulatory agencies may lack specific guidelines for evaluating these systems, which can lead to delays in approval and market access. Economic challenges, such as the high cost of developing and manufacturing TDDS, also play a role in limiting their widespread adoption. These factors contribute to the cautious approach observed among healthcare providers and patients, who may be hesitant to adopt new and unfamiliar technologies without clear evidence of their benefits and safety.

Moving forward, there is a need for continued research and development to address the challenges identified in this study. This includes conducting large-scale clinical trials to provide robust data on the safety and efficacy of TDDS, particularly for new and complex formulations. Regulatory agencies should work towards developing specific guidelines for TDDS, ensuring that these systems are evaluated consistently and rigorously. Clear regulatory frameworks will facilitate faster approval processes and encourage innovation in the field.

The pharmaceutical industry should invest in the development of more advanced and userfriendly TDDS, focusing on enhancing patient comfort and adherence. This includes exploring new materials and designs that cater to diverse patient needs and preferences. Additionally, efforts should be made to educate healthcare providers and patients about the benefits and proper use of TDDS, addressing any misconceptions or concerns that may hinder adoption.

The integration of TDDS with digital health technologies presents a promising avenue for personalized medicine. Future research should explore the potential of these integrated systems to provide real-time feedback on drug delivery and patient adherence, enabling more tailored and responsive treatment plans. This approach could significantly improve clinical outcomes and patient satisfaction, particularly in the management of chronic diseases.

Overall, the study highlights the transformative potential of TDDS in systemic disease management. While there are challenges to be addressed, the advancements in technology and materials, along with the positive patient experiences reported, suggest a bright future for these systems. Continued innovation and collaboration among stakeholders will be key to overcoming barriers and fully realizing the benefits of TDDS in clinical practice.

CONCLUSION

The most significant finding of this study is the demonstrated potential of transdermal drug delivery systems (TDDS) as a versatile and effective alternative for systemic disease management. The research highlighted advancements in technologies such as microneedles, iontophoresis, and ultrasound-assisted delivery, which have expanded the range of drugs that can be delivered transdermally. These technologies offer advantages including non-invasiveness, controlled release, and the avoidance of gastrointestinal metabolism, making them suitable for various therapeutic applications. The study also identified higher patient adherence rates associated with physical enhancement methods, suggesting a preference for these systems over chemical enhancers.

This study contributes to the existing body of knowledge by providing a comprehensive overview of the current state of TDDS, combining quantitative data from a literature review with qualitative insights from expert interviews. The integration of expert perspectives offered a nuanced understanding of practical challenges and opportunities in the field, particularly regarding regulatory and economic aspects. This dual approach not only highlighted the technical capabilities of TDDS but also emphasized the importance of patient-centered design in enhancing adherence and therapeutic outcomes. The research underscores the need for more user-friendly and comfortable TDDS designs to improve patient compliance.

A limitation of this study is the reliance on secondary data sources, which may not capture the latest unpublished advancements or proprietary developments in the field. Additionally, the qualitative component, though insightful, involved a relatively small sample size, which may not fully represent the diversity of opinions within the industry. These limitations suggest that further research is needed to explore new and emerging TDDS technologies, as well as to conduct largescale clinical trials that can provide more definitive evidence of their safety and efficacy. Understanding the long-term effects and potential risks associated with these systems is crucial for their broader adoption.

Future research should focus on overcoming the identified challenges, particularly in regulatory and economic domains. Developing standardized guidelines for the evaluation and approval of TDDS will be essential to facilitate their integration into mainstream medical practice. Further exploration of the integration of TDDS with digital health technologies could offer significant benefits in terms of personalized medicine and real-time patient monitoring. Continued innovation and interdisciplinary collaboration will be key to advancing TDDS technologies and realizing their full potential in improving patient care and outcomes in systemic disease management.

AUTHORS' CONTRIBUTION

Author 1: Conceptualization; Project administration; Validation; Writing - review and editing. Author 2: Conceptualization; Data curation; Investigation.

REFERENCES

- Chades, T., Le Fèvre, R., Chebbi, I., Blondeau, K., Guyot, F., & Alphanéry, E. (2024). Set-up of a pharmaceutical cell bank of *Magnetospirillum gryphiswaldense* MSR1 magnetotactic bacteria producing highly pure magnetosomes. *Microbial Cell Factories*, 23(1). <https://doi.org/10.1186/s12934-024-02313-4>

- Guo, B.-B., Liu, C., Zhu, C.-Y., Xin, J.-H., Zhang, C., Yang, H.-C., & Xu, Z.-K. (2024). Double charge flips of polyamide membrane by ionic liquid-decoupled bulk and interfacial diffusion for on-demand nanofiltration. *Nature Communications*, 15(1). <https://doi.org/10.1038/s41467024-46580-6>
- Joosse, I. R., van den Ham, H. A., Mantel-Teeuwisse, A. K., & Suleman, F. (2024). A proposed analytical framework for qualitative evaluation of access to medicines from a health systems perspective. *BMC Research Notes*, 17(1). <https://doi.org/10.1186/s13104-024-06764-1>
- Nagornii, D., Raymenants, F., Kaplaneris, N., & Noël, T. (2024). C(sp³)–H sulfinylation of light hydrocarbons with sulfur dioxide via hydrogen atom transfer photocatalysis in flow. *Nature Communications*, 15(1). <https://doi.org/10.1038/s41467-024-49322-w>
- Rao, J., Xie, J., Yuan, Q., Liu, D., Wang, Z., Lu, Y., Zheng, S., & Yang, Y. (2024). A variational expectation-maximization framework for balanced multi-scale learning of protein and drug interactions. *Nature Communications*, 15(1). <https://doi.org/10.1038/s41467-024-48801-4>
- Zhao, S., Zeng, D., Wang, M., & Jiang, X. (2024). C-SuFEx linkage of sulfonimidoyl fluorides and organotrifluoroborates. *Nature Communications*, 15(1). <https://doi.org/10.1038/s41467-02444998-6>

Copyright Holder :

© Pheny Lurn et.al (2025).

First Publication Right :

© Journal of Advanced Pharmaceutical Research Sciences and Sustainability (JAPRSS)

This article is under:

